Abstract:Aberrant DNA methylation plays a critical role in the development and progression of cancer. Failure to demethylate and to consequently reactivate methylation-silenced genes in cancer contributes to chemotherapeutic resistance, yet the regulatory mechanisms of DNA demethylation in response to chemotherapeutic agents remain unclear. Here, we show that promyelocytic leukemia (PML) recruits ten-eleven translocation dioxygenase 2 (TET2) to regulate DNA modification and cell proliferation in response to chemotherapeutic agents. TET2 was required by multiple chemotherapeutic agents (such as doxorubicin) to promote 5-hydroxymethylcytosine (5hmC) formation. Stable isotope labeling with amino acids in cell culture, followed by immunoprecipitation-mass spectrometry, identified potential binding partners of TET2, of which PML mostly enhanced 5hmC formation. PML physically bound to TET2 via the PML C-terminal domain and recruited TET2 to PML-positive nuclear bodies. This interaction was disrupted by the PML-RARA t(15;17) mutation, which stems from chromosomal translocation between DNA encoding the C-terminal domain of PML and the retinoic acid receptor alpha (RARA) gene. In response to chemotherapeutic drugs, PML recruited TET2, regulated DNA modification, reactivated methylation-silenced genes, and impaired cell proliferation. Knockout of PML abolished doxorubicin-promoted DNA modification. In addition, PML and TET2 levels positively correlated with improved overall survival in patients with head and neck cancer. These findings shed insight into the regulatory mechanisms of DNA modification in response to chemotherapeutic agents. Significance: Promyeloctic leukemia protein recruits TET2, regulating DNA modification and cell proliferation in response to chemotherapeutic agents. Cancer Res; 78(10); 1-15. ©2018 AACR.

CRL4(VprBP) E3 Ligase Promotes Monoubiquitylation and Chromatin Binding of TET Dioxygenases.

Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX

Genome-wide Analysis Reveals TET-and TDG-mediated 5-Methylcytosine Oxidation Dynamics

Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine.

Methyl-CpG-binding Domain Protein 3-Like 2 (MBD3L2) Promotes Tet2 Enzymatic Activity for Mediating 5mc Oxidation

CRL4DCAF8 Ubiquitin Ligase Targets Histone H3K79 and Promotes H3K9 Methylation in the Liver.

RNA m 5 C oxidation by TET2 regulates chromatin state and leukaemogenesis

Tet1 Regulates Dna Replication Through Targeting of Minichromosome Maintenance Genes

MBD3L2 promotes Tet2 enzymatic activity for mediating 5-methylcytosine oxidation.

RNA m5C oxidation by TET2 regulates chromatin state and leukaemogenesis

Isoform-specific and ubiquitination dependent recruitment of Tet1 to replicating heterochromatin modulates methylcytosine oxidation

Tet2 Activity is Modulated by Sirt1-Mediated Protein Deacetylation: A Potential Therapeutic Target in Myelodysplastic Syndrome

TET Enzymes Regulate Skeletal Development Through Increasing Chromatin Accessibility of RUNX2 Target Genes

Perturbing TET2 condensation promotes aberrant genome-wide DNA methylation and curtails leukaemia cell growth

TET is targeted for proteasomal degradation by the PHD-pVHL pathway to reduce DNA hydroxymethylation

Methylated DNMT1 and E2F1 Are Targeted for Proteolysis by L3MBTL3 and CRL4DCAF5 Ubiquitin Ligase

A Primary Role Of Tet Proteins In Establishment And Maintenance Of De Novo Bivalency At Cpg Islands

PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent.

TET (Ten-eleven translocation) family proteins: structure, biological functions and applications

Crystal Structure of TET2-DNA Complex: Insight into TET-Mediated 5mC Oxidation

Cytosine Modifications and Distinct Functions of TET1 on Tumorigenesis